Bionomics has announced plans to meet with the US Food & Drug Administration (FDA) in Q2 2024 following the release of positive topline data from a Phase IIb trial of its lead candidate BNC210 to ...

Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder (PTSD).

Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to ...

Wieser, W., and Hopper, B. E., Bull. Mus. Comp. Zool. (in the press). Meyers, S. P., and Hopper, B. E., Bull. Mar. Sci., 16 (1966) (in the press).